drugset / Trial / NCT00004106

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

NCT00004106 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying temozolomide to see how well it works in treating patients with mycosis fungoides or Sezary syndrome that has not responded to previous treatment.

Timeline

Start
1998-05
Primary completion
2006-04
Completion
2006-04

Outcome

Outcome not reported

Stopped (Enrollment): “Per Data Monitoring Committee given the poor/inadequate accrual.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 150 mg/m2 Oral

Indications